Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Tough-to-Treat myeloma: DREAMM 7 trial tests powerful combo

NCT ID NCT04246047

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated May 23, 2026 · Updated 1 time

Summary

This Phase 3 trial compares two drug combinations for people with multiple myeloma that has come back or stopped responding to treatment. About 494 participants receive either a new drug (belantamab mafodotin) plus standard drugs, or another approved combination. The goal is to see which works better at delaying cancer growth and improving response rates.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • GSK Investigational Site

    Yuma, Arizona, 85364, United States

  • GSK Investigational Site

    Denver, Colorado, 80218, United States

  • GSK Investigational Site

    Kansas City, Kansas, 66205, United States

  • GSK Investigational Site

    Fairfield, Ohio, 45242, United States

  • GSK Investigational Site

    Tyler, Texas, 75702, United States

  • GSK Investigational Site

    Liverpool, New South Wales, 2170, Australia

  • GSK Investigational Site

    Wollongong, New South Wales, 2500, Australia

  • GSK Investigational Site

    Benowa, Queensland, 4217, Australia

  • GSK Investigational Site

    Brussels, 1090, Belgium

  • GSK Investigational Site

    Brussels, 1200, Belgium

  • GSK Investigational Site

    Ghent, 9000, Belgium

  • GSK Investigational Site

    Roeselare, 8800, Belgium

  • GSK Investigational Site

    Beijing, 100191, China

  • GSK Investigational Site

    Jinan, 250012, China

  • GSK Investigational Site

    Shenyang, 110001, China

  • GSK Investigational Site

    Alexandroupoli, 68 100, Greece

  • GSK Investigational Site

    Athens, 11528, Greece

  • GSK Investigational Site

    Thessaloniki, 54007, Greece

  • GSK Investigational Site

    Tel Aviv, 64239, Israel

  • GSK Investigational Site

    Bergamo, 24127, Italy

  • GSK Investigational Site

    Meldola FC, 47014, Italy

  • GSK Investigational Site

    Milan, 20133, Italy

  • GSK Investigational Site

    Siena, 53100, Italy

  • GSK Investigational Site

    Aichi, 441-8570, Japan

  • GSK Investigational Site

    Aichi, 467-8602, Japan

  • GSK Investigational Site

    Aomori, 030-8553, Japan

  • GSK Investigational Site

    Ehime, 790-8524, Japan

  • GSK Investigational Site

    Fukuoka, 806-8501, Japan

  • GSK Investigational Site

    Fukuoka, 807-8555, Japan

  • GSK Investigational Site

    Fukuoka, 810-8563, Japan

  • GSK Investigational Site

    Fukuoka, 815-8555, Japan

  • GSK Investigational Site

    Gifu, 503-8502, Japan

  • GSK Investigational Site

    Gunma, 377-0280, Japan

  • GSK Investigational Site

    Hyōgo, 670-8540, Japan

  • GSK Investigational Site

    Kanagawa, 221-0855, Japan

  • GSK Investigational Site

    Kanagawa, 247-8533, Japan

  • GSK Investigational Site

    Kochi, 781-8555, Japan

  • GSK Investigational Site

    Nagano, 392-8510, Japan

  • GSK Investigational Site

    Okayama, 701-1192, Japan

  • GSK Investigational Site

    Osaka, 530-0012, Japan

  • GSK Investigational Site

    Osaka, 545-8586, Japan

  • GSK Investigational Site

    Shizuoka, 411-8777, Japan

  • GSK Investigational Site

    Dordrecht, 3318 AT, Netherlands

  • GSK Investigational Site

    Groningen, 9713 GZ, Netherlands

  • GSK Investigational Site

    Chorzów, 41-500, Poland

  • GSK Investigational Site

    Krakow, 30510, Poland

  • GSK Investigational Site

    Lodz, 93-513, Poland

  • GSK Investigational Site

    Lublin, 20-081, Poland

  • GSK Investigational Site

    Lublin, 20-090, Poland

  • GSK Investigational Site

    Nowy Sącz, 33-300, Poland

  • GSK Investigational Site

    Poznan, 60-569, Poland

  • GSK Investigational Site

    Warsaw, 02-781, Poland

  • GSK Investigational Site

    Moscow, 125284, Russia

  • GSK Investigational Site

    Nizhny Novgorod, 603126, Russia

  • GSK Investigational Site

    Novosibirsk, 630087, Russia

  • GSK Investigational Site

    Saint Petersburg, 191024, Russia

  • GSK Investigational Site

    Saint Petersburg, 197 089, Russia

  • GSK Investigational Site

    Saratov, 410028, Russia

  • GSK Investigational Site

    Ufa, 450083, Russia

  • GSK Investigational Site

    Pusan, 49241, South Korea

  • GSK Investigational Site

    Ulsan, 44033, South Korea

  • GSK Investigational Site

    Barcelona, 08035, Spain

  • GSK Investigational Site

    Barcelona, 08916, Spain

  • GSK Investigational Site

    Cáceres, 10003, Spain

  • GSK Investigational Site

    Gijón, 33394, Spain

  • GSK Investigational Site

    L'Hospitalet de Llobrega, 08908, Spain

  • GSK Investigational Site

    Murcia, 30008, Spain

  • GSK Investigational Site

    PamplonaNavarra, 31008, Spain

  • GSK Investigational Site

    Salamanca, 37007, Spain

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA